Advances of anaplastic lymphoma kinase in non-small cell lung cancer
10.3760/cma.j.issn.1673-422X.2014.08.011
- VernacularTitle:ALK 基因在非小细胞肺癌中的研究进展
- Author:
Shu FANG
;
Zhifeng PAN
- Publication Type:Journal Article
- Keywords:
Carcinoma,non-small-cell lung;
Anaplastic lymphoma kinase;
Molecular targeted therapy
- From:
Journal of International Oncology
2014;(8):592-595
- CountryChina
- Language:Chinese
-
Abstract:
Targeted therapy is the most prospective part of the research related to the treatment of non-small cell lung cancer(NSCLC). After epidermal growth factor receptor(EGFR),anaplastic lymphoma kinase (ALK)gene is expected to become a new target in the treatment of NSCLC. Moreover,several related resear-ches suggest that ALK inhibitor(crizotinib)is effective for treatment of ALK-rearranged NSCLC. Therefore,it is important to review the detection method of ALK gene,clinicopathologic features and the research progress of ALK inhibitor for the individual treatment of NSCLC.